CTI is developing medicines to help treat your cancer while maintaining your quality of life.
Pixantrone is marketed by CTI in the EU as Pixuvri®.Summary of Product Characteristics and Package Insert
Learn about our potential treatments for non-Hodgkin Lymphoma.See Phase 3 Pipeline
Learn about our potential treatments for Acute Myeloid Leukemia (AML), Myelodysplasia (MDS).See Phase 1 Pipeline
CTI Announces New Data Presented at EHA 2013 Congress Demonstrating the Safety and Tolerability Profile of Pacritinib in Patients with Myelofibrosis
New EXTEND Analyses Evaluate Efficacy of Single Agent PIXUVRIŽ in 3rd and 4th Line Salvage Setting With and Without Prior Rituximab Treatment
No events scheduledview all events
PIXUVRI is the only medicine approved as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-Cell lymphomas in the E.U.
Pixantrone is marketed in the E.U. as PIXUVRI | Learn more
Our late-stage development pipeline addresses a full complement of blood-related cancers.learn about our oncology pipeline